



THIRD EDITION

BARILE'S CLINICAL TOXICOLOGY

PRINCIPLES AND MECHANISMS

Frank A. Barile

Barile's Clinical Toxicology

Principles and Mechanisms,

Third Edition



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Barile's Clinical Toxicology

Principles and Mechanisms, Third Edition

Frank A. Barile, MS, PhD



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2019 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper

International Standard Book Number-13: 978-1-4987-6530-5 (Hardback)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

Pauline
through all the edits



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Contents

Preface.....	xxxix
Acknowledgments.....	xxxiii
Author	xxxv
Contributors	xxxvii

SECTION I *Introduction to Basic Toxicological Principles*

Chapter 1	Introduction	3
1.1	Introduction	3
1.2	Basic Definitions.....	4
1.2.1	Toxicology	4
1.2.2	Clinical Toxicology	4
1.3	Types of Toxicology	5
1.3.1	General Toxicology	5
1.3.2	Mechanistic Toxicology	5
1.3.3	Regulatory Toxicology	5
1.3.4	Descriptive Toxicology.....	6
1.4	Types of Toxicologist.....	7
1.4.1	Forensic Toxicologist.....	7
1.4.2	Clinical Toxicologist	8
1.4.3	Research Toxicologist.....	8
1.4.4	Regulatory Toxicologist	8
	References	8
	Suggested Readings.....	8
	Review Articles	9
Chapter 2	Risk Assessment and Regulatory Toxicology	11
2.1	Risk Assessment.....	11
2.1.1	Introduction	11
2.1.2	Hazard Identification/Risk Assessment (HIRA).....	11
2.1.3	Dose–Response Evaluation	11
2.1.4	Exposure Assessment and Assessment Modeling	12
2.1.5	Risk Characterization.....	14
2.2	Regulatory Toxicology	16
2.2.1	Nuclear Regulatory Commission (NRC)	16
2.2.2	Environmental Protection Agency (EPA)	17
2.2.3	The Food and Drug Administration (FDA)	18

2.2.4	Drug Enforcement Administration (DEA).....	19
2.2.5	Consumer Products Safety Commission (CPSC).....	20
2.2.6	Occupational Safety and Health Administrations (OSHA).....	22
	References	23
	Suggested Readings.....	23
	Review Articles	23
Chapter 3	Therapeutic Monitoring of Adverse Drug Reactions (ADRs).....	27
3.1	Adverse Drug Reactions (ADRs) in Clinical Practice	27
3.1.1	The Joint Commission (TJC)	27
3.1.2	Growing Medication Safety Concerns	28
3.1.3	National Patient Safety Goals (NPSG).....	28
3.2	Factors that Contribute to Adverse Drug Reactions (ADRs)	29
3.2.1	Inadequate Monitoring of Prescribed Drugs.....	29
3.2.2	Improper Adherence to Prescribed Directions	32
3.2.3	Over-Prescribing and Overuse of Medications	32
3.2.4	Drug–Drug and Drug–Disease Interactions	32
3.2.5	Allergic Reactions	32
3.2.6	Medication Warnings	33
3.2.7	Medication Errors.....	33
3.2.8	Adverse Drug Reactions (ADRS).....	33
3.3	Treatment of ADRs and Poisoning in Patients.....	35
3.3.1	History.....	35
3.3.2	Poison Control Centers (PCCs)	35
3.3.3	Clinical Management of ADRs.....	36
3.3.4	Clinical Management of Toxicologic Emergencies....	36
3.4	Drug Identification and Methods of Detection.....	41
	References	44
	Suggested Readings.....	44
	Review Articles	45
Chapter 4	Classification of Toxins in Humans.....	47
4.1	Introduction	47
4.2	Target Organ Classification	47
4.2.1	Agents Affecting the Hematopoietic System	47
4.2.2	Immunotoxic Agents	48
4.2.3	Hepatotoxic Agents	48
4.2.4	Nephrotoxic Agents.....	49
4.2.5	Pulmonary Toxic Agents.....	52
4.2.6	Agents Affecting the Nervous System	54
4.2.7	Agents Affecting the Cardiovascular (CV) System	55

4.2.8	Dermatotoxic Agents.....	55
4.2.9	Agents Affecting the Reproductive System	59
4.2.10	Agents Affecting the Endocrine System	59
4.3	Classification According to use in the Public Domain.....	60
4.3.1	Insecticides, Herbicides, Fungicides, and Rodenticides (Pesticides).....	60
4.3.2	Food and Color Additives.....	61
4.3.3	Therapeutic Drugs.....	63
4.3.4	By-Products of Combustion	63
4.4	Classification According to Source	63
4.4.1	Botanical	63
4.4.2	Environmental	63
4.5	Classification According to Effects.....	64
4.5.1	Pathologic	64
4.5.2	Teratogenic, Mutagenic, and Carcinogenic	64
4.6	Classification According to Physical State.....	64
4.6.1	Solids.....	64
4.6.2	Liquids.....	64
4.6.3	Gases	65
4.7	Classification According to Biochemical Properties.....	65
4.7.1	Chemical Structure	65
4.7.2	Mechanism of Action or Toxicity.....	65
	References	65
	Suggested Readings.....	65
	Review Articles	65
Chapter 5	Exposure.....	69
5.1	Introduction	69
5.2	Route of Exposure	69
5.2.1	Oral.....	69
5.2.2	Intranasal.....	70
5.2.3	Inhalation	71
5.2.4	Parenteral.....	71
5.3	Duration and Frequency	72
5.3.1	Acute Exposure	72
5.3.2	Chronic Exposure.....	73
5.3.3	Single- or Repeated-Dose Exposure	73
5.4	Accumulation.....	73
5.4.1	According to Physiological Compartment	74
5.4.2	According to Chemical Properties.....	74
5.4.3	According to Other Biological Factors.....	74
	References	76
	Suggested Readings.....	76
	Review Articles	76

Chapter 6	Effects.....	79
6.1	General Classification.....	79
6.1.1	Introduction to Principles of Immunology.....	79
6.1.2	Chemical Allergies.....	79
6.1.3	Idiosyncratic Reactions	86
6.1.4	Immediate versus Delayed Effects.....	86
6.1.5	Reversible versus Irreversible Reactions.....	86
6.1.6	Local versus Systemic Effects.....	86
6.1.7	Target Therapeutic Effects	87
6.2	Chemical Interactions.....	87
6.2.1	Potential.....	87
6.2.2	Additive	87
6.2.3	Synergistic.....	88
6.2.4	Antagonistic	88
	References	88
	Suggested Readings.....	88
	Review Articles.....	89
Chapter 7	Dose–Response	91
7.1	General Assumptions	91
7.1.1	Types of Dose–Response Relationships.....	91
7.1.2	Concentration–Effect and Presence at the Receptor Site	93
7.1.3	Criteria for Measurement	93
7.2	LD ₅₀ (Lethal Dose 50%).....	93
7.2.1	Definition.....	93
7.2.2	Experimental Protocol	93
7.2.3	Factors That Influence the LD ₅₀	94
7.3	ED ₅₀ (Effective Dose 50%), TD ₅₀ (Toxic Dose 50%), and TI (Therapeutic Index)	95
7.3.1	Relationship to LD ₅₀	95
7.3.2	Assumptions Using the TI.....	95
7.4	IC ₅₀ (Inhibitory Concentration 50%).....	96
7.4.1	Definition.....	96
7.4.2	Experimental Determination.....	97
7.4.3	For <i>In Vitro</i> Systems.....	97
	References	97
	Suggested Readings.....	97
	Review Articles	98
Chapter 8	Descriptive Animal Toxicity Tests.....	99
8.1	Correlation with Human Exposure.....	99
8.1.1	Human Risk Assessment.....	99

8.1.2	Predictive Toxicology and Extrapolation to Human Toxicity	99
8.2	Species Differentiation	99
8.2.1	Selection of a Suitable Animal Species.....	99
8.2.2	Cost-Effectiveness	100
8.2.3	Institutional Animal Care and Use Committee (IACUC).....	100
8.3	Descriptive Tests.....	101
8.3.1	Required LD50 and Two Routes	101
8.3.2	Chronic and Subchronic Exposure.....	101
8.3.3	Types of Tests	101
	References	102
	Suggested Readings.....	102
	Review Articles.....	103
Chapter 9	<i>In Vitro</i> Alternatives to Animal Toxicity	105
9.1	<i>In Vitro</i> Methods.....	105
9.1.1	Cell Culture Methods	105
9.1.2	Organ System Cytotoxicity	105
9.1.3	Applications to Clinical Toxicology.....	106
9.1.4	Relationship to Animal Experiments	107
9.2	Correlation with Human Exposure.....	107
9.2.1	Risk Assessment.....	107
9.2.2	Extrapolation to Human Toxicity	107
9.2.3	Predictive Toxicology	108
	References	108
	Suggested Readings.....	108
	Review Articles	108
Chapter 10	Toxicokinetics	111
10.1	Toxicokinetics.....	111
10.1.1	Relationship to Pharmacokinetics.....	111
10.1.2	One-Compartment Model	111
10.1.3	Two-Compartment Model	112
10.1.4	Application to Clinical Toxicology	112
10.2	Absorption	112
10.2.1	Ionic and Nonionic Principles	112
10.2.2	Henderson–Hasselbalch Equation and Degree of Ionization.....	114
10.2.3	Route of Administration and Solubility	118
10.2.4	Absorption in Nasal and Respiratory Mucosa	119
10.2.5	Transport of Molecules	120
10.3	Distribution.....	121
10.3.1	Fluid Compartments.....	121

10.3.2	Ionic and Nonionic Principles	122
10.3.3	Plasma Protein Binding.....	123
10.3.4	Lipids.....	125
10.3.5	Liver and Kidney.....	125
10.3.6	Blood–Brain Barrier.....	125
10.3.7	Placenta	125
10.3.8	Other Factors Affecting Distribution	126
10.4	Biotransformation (Metabolism)	126
10.4.1	Principles of Detoxification.....	126
10.4.2	Phase I Reactions	127
10.4.3	Phase II Reactions	128
10.5	Elimination.....	131
10.5.1	Urinary	131
10.5.1.1	First-Order Elimination	132
10.5.1.2	Zero-Order Elimination.....	134
10.5.2	Fecal	135
10.5.3	Pulmonary.....	135
10.5.4	Mammary Glands	136
10.5.5	Secretions	136
	References	136
	Suggested Readings.....	136
	Review Articles	137
Chapter 11	Chemical– and Drug–Receptor Interactions.....	139
	<i>Zacharoula Konsoula</i>	
11.1	Types of Chemical and Drug Receptors.....	139
11.1.1	Ion Channels.....	139
11.1.2	G-Protein-Coupled Receptors	142
11.1.3	Kinases and Enzyme-Coupled Receptors.....	143
11.1.4	Intracellular Receptors	145
11.2	Signal Transduction.....	148
	References	150
	Suggested Readings.....	150
	Review Articles	150
Chapter 12	Toxicogenomics.....	151
	<i>Anirudh J. Chintalapati, Zacharoula Konsoula, and Frank A. Barile</i>	
12.1	Introduction	151
12.2	Human Genomic Variation.....	151
12.2.1	Genomic Variation in Target Molecules	152
12.2.2	Genomic Variation in Drug Metabolism.....	154
12.3	Gene Structure and Function.....	154
12.3.1	DNA Alterations and Genotoxic Effects.....	155

12.3.2	DNA Repair Mechanisms	157
12.3.3	Experimental Monitoring for Genetic Toxicity.....	159
12.3.4	Clinical Monitoring for Genetic Toxicity.....	159
12.4	Epigenetic Toxicology	160
12.4.1	Mechanisms of Epigenetic Toxicity	161
12.4.1.1	DNA Methylation	161
12.4.1.2	Posttranslational Modifications of Histone Proteins.....	162
12.4.1.3	Noncoding RNA.....	162
12.4.2	Epigenetics and Disease	163
	Referenes.....	163
	Suggested Readings.....	163
	Review Articles	164

SECTION II Toxicity of Therapeutic Agents

Chapter 13	Sedative/Hypnotics.....	167
-------------------	-------------------------	-----

Frank A. Barile and Anirudh J. Chintalapati

13.1	Barbiturates	167
13.1.1	History and Classification	167
13.1.2	Epidemiology	167
13.1.3	Medicinal Chemistry.....	167
13.1.4	Pharmacology and Clinical Use.....	168
13.1.5	Toxicokinetics and Metabolism.....	168
13.1.6	Mechanism of Toxicity.....	169
13.1.7	Signs and Symptoms of Acute Toxicity	169
13.1.8	Emergency Guidelines	171
13.1.9	Clinical Management of Acute Overdose	171
13.1.10	Tolerance and Withdrawal.....	172
13.1.11	Methods of Detection.....	172
13.2	Benzodiazepines (BZ).....	172
13.2.1	Epidemiology	172
13.2.2	Medicinal Chemistry.....	173
13.2.3	Pharmacology and Mechanism of Toxicity.....	173
13.2.4	Toxicokinetics	173
13.2.5	Signs and Symptoms of Acute Toxicity	174
13.2.6	Emergency Guidelines	174
13.2.7	Clinical Management of Acute Overdose	174
13.2.8	Tolerance and Withdrawal.....	174
13.2.9	Methods of Detection.....	174
13.3	Miscellaneous Sedative/Hypnotics	176
13.3.1	Chloral Hydrate.....	176
13.3.2	Meprobamate (Miltown®, Equanil®).....	176

13.3.3	Zolpidem Tartrate (Ambien®).....	177
13.3.4	Buspirone (Buspar®).....	177
13.3.5	Flunitrazepam (Rohypnol®).....	177
13.3.6	Gamma-Hydroxybutyrate (GHB).....	178
13.3.7	Ethchlorvynol (Placidyl®), Methaqualone (Quaalude®), Glutethimide (Doriden®), Methyprylon (Noludar®).....	178
13.4	Methods of Detection and Laboratory Tests for S/H	179
	References	179
	Suggested Readings.....	180
	Review Articles	181
Chapter 14	Opioids and Related Agents	183
14.1	Opioids.....	183
14.1.1	U.S. Public Health and Historical Use	183
14.1.2	Neonatal Abstinence Syndrome (NAS)	185
14.1.3	Classification	186
14.1.4	Medicinal Chemistry.....	189
14.1.5	Mechanism of Toxicity.....	189
14.1.6	Brain Chemistry	191
14.1.7	Toxicokinetics	191
14.1.8	Mechanism of Toxicity.....	191
14.1.9	Signs and Symptoms of Clinical Toxicity.....	192
14.1.10	Clinical Management of Acute Overdose	192
14.1.11	Tolerance and Withdrawal.....	193
14.1.12	Clinical Management of Addiction	195
14.2	Specific Opioid Derivatives	195
14.2.1	Codeine.....	195
14.2.2	Diphenoxylate.....	196
14.2.3	Fentanyl	196
14.2.4	Meperidine	196
14.2.5	Pentazocine	197
14.2.6	Propoxyphene.....	197
14.2.7	Hydrocodone/Oxycodone	197
14.2.8	Tramadol	198
14.2.9	Clonidine	199
14.3	Methods of Detection	199
	References	200
	Suggested Readings.....	200
	Review Articles	201
Chapter 15	Sympathomimetics	203
15.1	Amphetamines and Amphetamine-like Agents	203
15.1.1	Incidence	203

15.1.2	Classification	203
15.1.3	Medicinal Chemistry.....	204
15.1.4	Pharmacology and Clinical Use.....	204
15.1.5	Toxicokinetics	206
15.1.6	Effects and Mechanism of Toxicity.....	206
15.1.7	Chronic Methamphetamine Use	208
15.1.8	Tolerance and Withdrawal.....	208
15.1.9	Clinical Management of Amphetamine Addiction.....	208
15.1.10	Methods of Detection.....	209
15.2	Cocaine.....	209
15.2.1	Incidence and Occurrence.....	209
15.2.2	Medicinal Chemistry.....	210
15.2.3	Pharmacology and Clinical Use.....	210
15.2.4	Toxicokinetics	211
15.2.5	Signs and Symptoms of Acute Toxicity	212
15.2.6	Clinical Management of Acute Overdose	212
15.2.7	Tolerance and Withdrawal.....	213
15.2.8	Clinical Management of Cocaine Addiction.....	213
15.2.9	Methods of Detection.....	213
15.3	Xanthine Derivatives	213
15.3.1	Source and Medicinal Chemistry.....	213
15.3.2	Occurrence	214
15.3.3	Pharmacology and Clinical Use.....	214
15.3.4	Toxicokinetics	216
15.3.5	Signs and Symptoms and Clinical Management of Caffeine Toxicity.....	216
15.3.6	Signs and Symptoms and Clinical Management of Theophylline Toxicity	217
15.3.7	Tolerance and Withdrawal.....	217
15.4	Other Specific Sympathomimetic Agents	217
15.4.1	Strychnine	217
15.4.2	Nicotine	218
15.4.3	Ephedrine	219
15.4.4	Phenylpropranolamine	220
15.4.5	Pseudoephedrine	220
	References	220
	Suggested Readings.....	220
	Review Articles	221
Chapter 16	Hallucinogenic Agents	225
16.1	History and Description	225
16.2	Ergot Alkaloids.....	225
16.2.1	Incidence and Occurrence.....	225
16.2.2	Medicinal Chemistry.....	226
16.2.3	Pharmacology and Clinical Use.....	226

16.2.4	Signs and Symptoms of Acute Toxicity	227
16.2.5	Clinical Management of Acute Overdose	227
16.3	Lysergic Acid Diethylamide (LSD).....	228
16.3.1	Incidence and Occurrence.....	228
16.3.2	Mechanism of Toxicity.....	228
16.3.3	Hallucinogenic Effects	228
16.3.4	Toxicokinetics	229
16.3.5	Signs and Symptoms of Acute Toxicity	229
16.3.6	Clinical Management of Acute Overdose	229
16.3.7	Tolerance and Withdrawal.....	230
16.3.8	Methods of Detection.....	230
16.4	Tryptamine Derivatives.....	230
16.4.1	Incidence and Occurrence.....	230
16.4.2	Mechanism of Toxicity.....	230
16.4.3	Signs and Symptoms of Acute Toxicity	231
16.4.4	Clinical Management of Acute Overdose	231
16.4.5	Tolerance and Withdrawal.....	231
16.4.6	Methods of Detection.....	231
16.5	Phenethylamine Derivatives.....	232
16.5.1	Incidence and Occurrence.....	232
16.5.2	Medicinal Chemistry.....	232
16.5.3	Mescaline	232
16.5.4	DOM (2,5-dimethoxy-4-methylamphetamine, STP) and MDA (3,4-methylene- dioxyamphetamine).....	234
16.5.5	MDMA (3,4-methylenedioxymethamphetamine, ecstasy)	234
16.5.6	Methods of Detection.....	235
16.6	Phencyclidine (1-Phenylcyclohexyl Piperidine; PCP)	235
16.6.1	Incidence and Occurrence.....	235
16.6.2	Toxicokinetics	235
16.6.3	Signs and Symptoms of Acute Toxicity	236
16.6.4	Clinical Management of Acute Overdose	236
16.6.5	Tolerance and Withdrawal.....	237
16.6.6	Methods of Detection.....	237
16.7	Marijuana.....	237
16.7.1	Incidence and Occurrence.....	237
16.7.2	Medicinal Chemistry.....	240
16.7.3	Receptor Pharmacology and Toxicology	240
16.7.4	Clinical Use and Effects.....	241
16.7.5	Toxicokinetics	242
16.7.6	Acute Toxicity and Clinical Management.....	242
16.7.7	Tolerance, Withdrawal, and Chronic Effects	243
16.7.8	Clinical Management of Chronic Addiction	243
16.7.9	Methods of Detection.....	243
16.8	Miscellaneous Hallucinogenic Agents	244

16.8.1	Ketamine (Special K, Vitamin K).....	244
16.8.2	Gamma-hydroxybutyrate (GHB; Xyrem®).....	245
16.8.3	NBOMe	246
	References	246
	Suggested Readings.....	246
	Review Articles	247
Chapter 17	Anticholinergic and Neuroleptic Drugs	251
17.1	Introduction to Drugs Possessing Anticholinergic Effects.....	251
17.2	Antihistamine, Gastrointestinal, and Antiparkinson Drugs.....	251
17.2.1	Incidence	251
17.2.2	Medicinal Chemistry, Pharmacology, and Clinical Use.....	253
17.2.3	Signs and Symptoms of Acute Toxicity	253
17.2.4	Clinical Management of Acute Overdose	254
17.2.5	Methods of Detection.....	254
17.3	Tricyclic Antidepressants (TCA).....	255
17.3.1	Incidence	255
17.3.2	Medicinal Chemistry.....	255
17.3.3	Pharmacology and Clinical Use.....	255
17.3.4	Toxicokinetics	255
17.3.5	Mechanism of Toxicity.....	256
17.3.6	Signs and Symptoms of Acute Toxicity	256
17.3.7	Clinical Management of Acute Overdose	256
17.3.8	Tolerance and Withdrawal.....	259
17.3.9	Methods of Detection.....	259
17.4	Phenothiazine, Phenylbutylpiperidine, and Thioxanthine Antipsychotics	259
17.4.1	Classification and Indications.....	259
17.4.2	Pharmacology and Clinical Use.....	260
17.4.3	Toxicokinetics	260
17.4.4	Mechanism and Signs and Symptoms of Acute Toxicity.....	260
17.4.5	Clinical Management of Acute Overdose	262
17.4.6	Tolerance and Withdrawal.....	262
17.4.7	Methods of Detection.....	262
17.5	Selective Serotonin Reuptake Inhibitors (SSRIS)	262
17.5.1	Classification and Clinical Use	262
17.5.2	Pharmacology and Receptor Activity	263
17.5.3	Toxicokinetics	264
17.5.4	Side Effects and Adverse Reactions.....	265
17.5.5	Signs and Symptoms of Acute Toxicity	266
17.5.6	Clinical Management of Acute Overdose (O.D.).....	266
17.5.7	Tolerance and Withdrawal.....	267
17.5.8	Methods of Detection.....	267

References	267
Suggested Readings.....	267
Review Articles	268
Chapter 18 Acetaminophen, Salicylates, and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).....	271
18.1 History and Description	271
18.2 Acetaminophen (N-Acetyl-Para-Aminophenol, APAP, Paracetamol)	271
18.2.1 Incidence	271
18.2.2 Medicinal Chemistry and Pharmacology	272
18.2.3 Clinical Use.....	272
18.2.4 Metabolism and Mechanism of Toxicity	272
18.2.5 Signs and Symptoms of Acute Toxicity	274
18.2.6 Clinical Management of Acute Overdose	274
18.3 Salicylates and Acetylsalicylic Acid (ASPIRIN, ASA).....	276
18.3.1 Incidence and Clinical Use	276
18.3.2 Toxicokinetics	277
18.3.3 Mechanism of Toxicity.....	277
18.3.4 Signs and Symptoms of Acute Toxicity	278
18.3.5 Clinical Management of Toxicity.....	279
18.4 Nonsteroidal Anti-Inflammatory Agents (NSAIDS)	281
18.4.1 History and Description	281
18.4.2 Classification, Pharmacology, and Clinical Use	282
18.4.3 Signs and Symptoms of Acute Toxicity	282
18.4.4 Clinical Management of Acute Overdose	282
18.5 Methods of Detection	284
References	284
Suggested Readings.....	284
Review Articles	285
Chapter 19 Anabolic–Androgenic Steroids	287
19.1 The Endocrine System.....	287
19.2 Neuroendocrine Physiology	287
19.2.1 Description	287
19.3 Anabolic–Androgenic Steroids (AAS).....	288
19.3.1 Definition and Incidence	288
19.3.2 Pharmacology and Clinical Use.....	289
19.3.3 Adverse reactions	289
19.3.4 Addiction and Withdrawal Syndrome.....	293
19.3.5 Treatment of the Consequences of Chronic Steroid Use	293
19.4 Estrogen and Progestins	293
19.4.1 Physiology	293

19.4.2	Pharmacology and Clinical Use.....	294
19.4.3	Clinical Toxicity of Prolonged Estrogen and/or Progestin Administration	294
	References	297
	Suggested Readings.....	297
	Review Articles	297
Chapter 20	Cardiovascular Toxicology.....	299
20.1	Epidemiology.....	299
20.2	Cardiovascular (CV) Physiology	299
20.2.1	CV Functions.....	299
20.2.2	Cardiac Circulation	300
20.2.3	Electrophysiology	300
20.2.4	The Conducting System	301
20.2.5	Electrocardiography	302
20.3	Digitalis Glycosides.....	303
20.3.1	Medicinal Chemistry.....	303
20.3.2	Pharmacology and Clinical Use.....	304
20.3.3	Toxicokinetics	304
20.3.4	Clinical Manifestations of Toxicity.....	305
20.3.5	Mechanisms of Toxicity	305
20.3.6	Clinical Management of Intoxication.....	306
20.3.7	Methods of Detection.....	307
20.4	Beta-Adrenergic Receptor Antagonists.....	307
20.4.1	β -Adrenergic Receptor System.....	307
20.4.2	Pharmacology and Clinical Use.....	307
20.4.3	Clinical Manifestations of Toxicity.....	308
20.4.4	Clinical Management of Intoxication.....	308
20.5	Calcium Channel Antagonists (Ca ²⁺ Channel Blockers).....	309
20.5.1	Pharmacology and Clinical Use.....	309
20.5.2	Clinical Manifestations of Toxicity.....	310
20.5.3	Clinical Management of Intoxication.....	310
20.6	Other CV Drugs	310
20.6.1	Angiotensin-Converting Enzyme (ACE) Inhibitors	311
20.6.2	Direct Vasodilators.....	312
20.6.3	Antiarrhythmic Drugs.....	313
	References	314
	Suggested Readings.....	314
	Review Articles	315
Chapter 21	Antineoplastic Agents	317
21.1	Description	317
21.2	Review of the Cell Cycle	317

21.3	Antimetabolites	318
21.3.1	Pharmacology and Clinical Use.....	318
21.3.2	Acute Toxicity	319
21.3.3	Clinical Management of Acute Overdose	319
21.4	Alkylating Agents.....	320
21.4.1	Pharmacology and Clinical Use.....	320
21.4.2	Acute Toxicity	320
21.4.3	Clinical Management of ADRs.....	321
21.5	Miscellaneous Chemotherapeutic Drugs.....	321
21.5.1	Natural Products.....	321
21.5.2	Hormones and Antagonists	323
21.5.3	Platinum Coordination Complexes	324
21.5.4	Substituted Urea	324
	References	325
	Suggested Readings.....	325
	Review Articles	325
Chapter 22	Vitamins	329
22.1	Introduction	329
22.2	Fat-Soluble Vitamins	331
22.2.1	Vitamin A and Retinoic Acid Derivatives	331
22.2.2	Vitamin D.....	332
22.2.3	Vitamin E.....	335
22.2.4	Vitamin K.....	335
22.3	Water-Soluble Vitamins.....	336
22.3.1	Thiamine	336
22.3.2	Riboflavin	336
22.3.3	Niacin	336
22.3.4	Folic Acid	338
22.3.5	Cyanocobalamin (Vitamin B ₁₂).....	338
22.3.6	Ascorbic Acid (Vitamin C)	338
22.3.7	Pyridoxine (Vitamin B ₆)	339
22.3.8	Pantothenic Acid (Vitamin B ₅)	339
	References	340
	Suggested Readings.....	340
	Review Articles	340
Chapter 23	Herbal Remedies	343
23.1	Introduction	343
23.2	Nomenclature and Classification.....	344
23.2.1	Nomenclature	344
23.2.2	Therapeutic Category	345
23.3	Indications	345

23.4 Other Therapeutic and Toxicologic Information on Herbal Products	345
References	356
Suggested Readings.....	356
Review Articles	357

SECTION III Toxicity of Nontherapeutic Agents

Chapter 24 Alcohols and Aldehydes.....	361
24.1 Ethanol.....	361
24.1.1 Incidence and Occurrence.....	361
24.1.2 Chemical Characteristics	361
24.1.3 Toxicokinetics	362
24.1.4 Calculation of Blood Alcohol Concentrations (BAC)	363
24.1.5 Mechanisms of Toxicity	364
24.1.6 Clinical Manifestations of Acute Toxicity	366
24.1.7 Management of Acute Intoxication	368
24.1.8 Clinical Manifestations of Chronic Toxicity.....	368
24.1.9 Management of Chronic Intoxication.....	370
24.1.10 Fetal Alcohol Syndrome (FAS).....	371
24.1.11 Tolerance, Dependence, and Withdrawal.....	371
24.1.12 Methods of Detection	372
24.2 Methanol.....	373
24.2.1 Incidence and Occurrence.....	373
24.2.2 Toxicokinetics	373
24.2.3 Mechanism of Toxicity.....	373
24.2.4 Clinical Manifestations of Acute Intoxication	374
24.2.5 Management of Acute Intoxication	374
24.3 Isopropanol.....	374
24.3.1 Toxicokinetics	375
24.3.2 Mechanisms of Toxicity	375
24.3.3 Clinical Manifestations of Acute Toxicity	375
24.3.4 Management of Acute Intoxication	375
24.4 Formaldehyde	375
24.4.1 Incidence and Occurrence.....	376
24.4.2 Toxicokinetics	376
24.4.3 Mechanisms of Toxicity	377
24.4.4 Clinical Manifestations of Acute Intoxication	377
24.4.5 Management of Acute Intoxication	377
References	377
Suggested Readings.....	377
Review Articles	378

Chapter 25	Gases	381
25.1	Introduction	381
25.2	Pulmonary Irritants	381
25.3	Simple Asphyxiants	382
25.3.1	Introduction	382
25.3.2	Gaseous Agents	382
25.4	Toxic Products of Combustion (TCP)	387
25.4.1	Introduction	387
25.4.2	Clinical Toxicity	387
25.5	Lacrimating Agents (Tear Gas)	389
25.5.1	Introduction	389
25.5.2	Chemical Agents	389
25.6	Chemical Asphyxiants	389
25.7	Carbon Monoxide (CO)	389
25.7.1	Incidence	389
25.7.2	Chemical Characteristics and Sources of Exposure	391
25.7.3	Toxicokinetics	391
25.7.4	Mechanism of Toxicity	391
25.7.5	Signs and Symptoms of Acute Toxicity	392
25.7.6	Treatment of Acute Poisoning	393
25.8	Cyanide	394
25.8.1	Chemical Characteristics, Occurrence, and Uses	394
25.8.2	Mechanism of Toxicity	394
25.8.3	Toxicokinetics	394
25.8.4	Signs and Symptoms of Acute Toxicity	395
25.8.5	Treatment of Acute Poisoning	395
25.9	Methods Of Detection	397
	References	397
	Suggested Readings	397
	Review Articles	398
Chapter 26	Metals	401
	<i>Anirudh J. Chintalapati and Frank A. Barile</i>	
26.1	Introduction	401
26.1.1	Background	401
26.1.2	Exposure and Applications	401
26.1.3	Physiological Role of Metals	402
26.2	Chelation Therapy	402
26.2.1	Description	402
26.2.2	Dimercaprol	404
26.2.3	Ethylenediaminetetraacetic Acid (EDTA)	404
26.2.4	Penicillamine	405
26.2.5	Deferoxamine	406

26.2.6	Succimer.....	406
26.2.7	Unithiol.....	407
26.3	Antimony.....	407
26.3.1	Physical and Chemical Properties.....	407
26.3.2	Occurrence and Uses.....	407
26.3.3	Mechanism of Toxicity.....	408
26.3.4	Toxicokinetics.....	408
26.3.5	Signs and Symptoms of Acute Poisoning.....	408
26.3.6	Treatment of Acute Poisoning.....	408
26.4	Arsenic (As).....	409
26.4.1	Physical and Chemical Properties.....	409
26.4.2	Occurrence and Uses.....	409
26.4.3	Mechanisms of Toxicity.....	409
26.4.4	Toxicokinetics.....	409
26.4.5	Signs and Symptoms of Acute Toxicity.....	410
26.4.6	Signs and Symptoms of Chronic Toxicity.....	410
26.4.7	Treatment of Acute Poisoning.....	410
26.4.8	Treatment of Chronic Poisoning.....	411
26.4.9	Carcinogenesis.....	411
26.5	Asbestos.....	411
26.5.1	Physical and Chemical Properties.....	411
26.5.2	Occurrence and Uses.....	411
26.5.3	Mechanism of Toxicity.....	412
26.5.4	Toxicokinetics.....	412
26.5.5	Signs and Symptoms of Acute Toxicity.....	412
26.5.6	Signs and Symptoms of Chronic Toxicity.....	412
26.5.7	Treatment of Acute Poisoning.....	413
26.5.8	Treatment of Chronic Poisoning.....	413
26.6	Cadmium.....	413
26.6.1	Physical and Chemical Properties.....	413
26.6.2	Occurrence and Uses.....	413
26.6.3	Mechanism of Toxicity.....	414
26.6.4	Toxicokinetics.....	414
26.6.5	Signs and Symptoms of Acute Toxicity.....	414
26.6.6	Signs and Symptoms of Chronic Toxicity.....	415
26.6.7	Treatment of Acute Poisoning.....	415
26.6.8	Treatment of Chronic Poisoning.....	415
26.7	Cobalt.....	415
26.7.1	Physical and Chemical Properties.....	415
26.7.2	Occurrence and Uses.....	415
26.7.3	Mechanism of Toxicity.....	416
26.7.4	Toxicokinetics.....	416
26.7.5	Signs and Symptoms of Acute Toxicity.....	416
26.7.6	Signs and Symptoms of Chronic Toxicity.....	416
26.7.7	Treatment of Acute Poisoning.....	417
26.7.8	Treatment of Chronic Poisoning.....	417

26.8	Copper	417
26.8.1	Physical and Chemical Properties.....	417
26.8.2	Occurrence and Uses.....	417
26.8.3	Mechanism of Toxicity.....	418
26.8.4	Toxicokinetics	418
26.8.5	Signs and Symptoms of Acute Toxicity	419
26.8.6	Signs and Symptoms of Chronic Toxicity.....	419
26.8.7	Treatment of Acute Poisoning.....	419
26.8.8	Treatment of Chronic Poisoning	419
26.9	Iron (Fe^{2+} , Fe^{3+}).....	420
26.9.1	Physical and Chemical Properties.....	420
26.9.2	Occurrence and Uses.....	420
26.9.3	Mechanism of Toxicity.....	420
26.9.4	Toxicokinetics	421
26.9.5	Signs and Symptoms of Acute Toxicity	422
26.9.6	Signs and Symptoms of Chronic Toxicity.....	422
26.9.7	Treatment of Acute Poisoning.....	422
26.9.8	Treatment of Chronic Poisoning	423
26.9.9	Clinical Monitoring.....	423
26.10	Lead.....	423
26.10.1	Physical and Chemical Properties.....	423
26.10.2	Occurrence and Uses.....	423
26.10.3	Mechanism of Toxicity.....	424
26.10.4	Toxicokinetics	424
26.10.5	Signs and Symptoms of Acute Toxicity	426
26.10.6	Signs and Symptoms of Chronic Toxicity.....	426
26.10.7	Treatment of Acute Poisoning.....	426
26.10.8	Treatment of Chronic Poisoning	427
26.10.9	Clinical Monitoring.....	427
26.11	Mercury (Hg).....	427
26.11.1	Physical and Chemical Properties.....	427
26.11.2	Occurrence and Uses.....	427
26.11.3	Occupational and Environmental Exposure.....	429
26.11.4	Mechanism of Toxicity.....	429
26.11.5	Toxicokinetics	429
26.11.6	Signs and Symptoms of Acute Toxicity (Inhalation and Ingestion)	430
26.11.7	Signs and Symptoms of Subacute or Chronic Poisoning	431
26.11.8	Clinical Management of Hg Poisoning	431
26.12	Selenium (Se).....	431
26.12.1	Physical and Chemical Properties.....	431
26.12.2	Occurrence and Uses.....	431
26.12.3	Physiological Role	432
26.12.4	Mechanism of Toxicity.....	432
26.12.5	Toxicokinetics	432